


PHARMACEUTICAL 2020



PHIBRO ANIMAL HEALTH CORP Rank 62 of 362





PHARMACEUTICAL 2020





PHIBRO ANIMAL HEALTH CORP Rank 62 of 362

The relative strengths and weaknesses of PHIBRO ANIMAL HEALTH CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PHIBRO ANIMAL HEALTH CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 539% points. The greatest weakness of PHIBRO ANIMAL HEALTH CORP is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 334% points.

The company's Economic Capital Ratio, given in the ranking table, is 71%, being 374% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	466,162
Cost of Goods Sold	563,371
Intangible Assets	74,826
Liabilities, Current	154,227
Liabilities, Non-Current	42,794
Other Assets	45,448
Other Compr. Net Income	-9,698
Other Expenses	16,792
Other Liabilities	313,635
Other Net Income	-11,721
Property and Equipment	140,235
Research and Development	0
Revenues	827,995
Selling, General and Administrative Expense	181,398

Output Variable	Value in 1000 USD
Assets	726,671
Liabilities	510,656
Expenses	761,561
Stockholders Equity	216,015
Net Income	54,713
Comprehensive Net Income	49,864
Economic Capital Ratio	71%